Neonatology · Neonatal Erythroderma–Autoinflammation–Inflammatory Bowel Disease Syndrome

Targeted Treatment: From Stabilization to Advanced Therapies

At a Glance

Treatment starts with newborn intensive care to support the skin and gut, provide nutrition, control temperature, and reduce infection risks. A genetic result may guide targeted immune medicines, stem cell transplant evaluation, or clinical-trial discussions.

Treatment for a newborn with erythroderma (severe skin redness), autoinflammation, and VEO-IBD (Very-Early-Onset IBD) is a two-step process. First, the medical team works to stabilize your baby’s health and manage infection risks in the NICU. Second, once a genetic variant or functional defect is identified, they evaluate options for “precision medicine”—treatments that target the specific biological cause of the illness ^[1]^[2].

Step 1: Supportive Care in the NICU

Before a genetic diagnosis is even confirmed, the NICU team must carefully manage the infant’s compromised skin and gut ^[3]. These interventions are highly individualized and carry their own risks.

Total Parenteral Nutrition (TPN): While enteral or elemental feeding is continued when safe, your baby may receive nutrition directly through a vein (IV). TPN ensures the baby has the energy needed to grow, but carries significant risks, including central line infection, thrombosis, and cholestatic liver injury ^[4]^[5].
Skin Barrier Management: To protect the fragile skin, nurses will use specialized emollients (like petrolatum-based ointments). Wet wraps may be utilized, though their appropriateness depends heavily on whether the skin is intact, weeping, or infected ^[6].
Infection Prophylaxis: Because your baby’s immune system is weakened—and treatments may suppress it further—they may receive prophylactic (preventative) medicines. This can include antibiotics, antivirals, and antifungals, but these are specialist-directed decisions, not automatic for every infant ^[1]^[7].
Temperature Control: Because erythroderma makes it hard for babies to stay warm, they are often kept in high-tech incubators with precise temperature controls ^[8].

Step 2: Targeted “Precision” Therapies

Once the genetic cause is known, your doctors may choose medications that target the specific biological pathway ^[2]. These treatments are frequently off-label, investigational, or specialist-selected, and carry substantial risks of suppressing the immune system.

Treatment Pathways by Genetic Finding

The following illustrates how a genetic result can influence specialist-directed treatment:

If the Genetic Finding is…	The Targeted Treatment may be…
IL10R Deficiency	Anakinra (an IL-1 inhibitor) is sometimes used off-label to calm inflammation as a bridge to a stem cell transplant ^[9]^[10].
NLRC4 Mutation	Doctors may consider IL-1 inhibitors (like canakinumab) or IL-18 blockers (investigational) to stop the overactive inflammation ^[11]^[12].
Omenn Syndrome (SCID)	This condition typically requires urgent evaluation for Hematopoietic Stem Cell Transplant (HSCT) to replace the immune system ^[13]^[14].
XIAP Deficiency	Targeted biologics (like infliximab or ustekinumab) are sometimes utilized off-label, while HSCT may be evaluated for severe disease ^[15]^[16].

The Role of Stem Cell Transplant (HSCT)

For many severe immunodeficiencies, Hematopoietic Stem Cell Transplant (HSCT)—often called a bone marrow transplant—is evaluated to “replace” the faulty immune system with a healthy one ^[17]^[18].

While it can be life-saving for selected disorders (like SCID/Omenn), HSCT is not indicated for every child, may not correct defects outside the blood/immune system, and carries profound risks. A transplant involves:

Conditioning: Using chemotherapy or specialized medicines to clear out the baby’s old immune cells. This carries high risks of organ toxicity ^[19].
Infusion: Healthy stem cells from a donor are given to the baby ^[17].
Engraftment and Risks: The wait for new cells to grow. Major risks include severe infection, graft failure, organ injury, and Graft-Versus-Host Disease (GVHD), where the donor cells attack the baby ^[17].

Clinical Trials

Because these conditions are so rare, your baby’s team may discuss clinical trials. These are research studies that offer access to newer therapies that are not yet widely available ^[20]. Choosing to participate is a personal decision, and your team will provide detailed information to help you decide.

Common questions in this guide

What is the first treatment step for a newborn with erythroderma and VEO-IBD?

The first step is usually intensive newborn care to stabilize the baby, protect the damaged skin, support nutrition, control body temperature, and reduce infection risks. The exact plan depends on the skin and bowel condition and may change as testing provides more information.

Why might a baby with VEO-IBD need TPN?

Total parenteral nutrition, or TPN, provides calories and nutrients through a vein when feeding through the gut is not safe or sufficient. It can support growth, but the care team must monitor for central-line infections, blood clots, and liver injury.

How can genetic testing change treatment for neonatal erythroderma?

A genetic result can identify an overactive or faulty immune pathway and help specialists choose a more targeted treatment. These medicines may be off-label or investigational, and the result may also prompt evaluation for a stem cell transplant.

When might a stem cell transplant be considered for an affected infant?

A hematopoietic stem cell transplant may be urgently evaluated for selected severe immune disorders, including SCID with Omenn syndrome, and for some other severe genetic conditions. It is not appropriate for every child and can cause serious complications such as infection, organ injury, graft failure, and graft-versus-host disease.

What do medicines such as anakinra or infliximab do?

These medicines reduce specific immune signals that can drive harmful inflammation. The choice depends on the baby’s genetic or functional findings, and treatment requires close monitoring because immune suppression can increase infection risk.

Could a clinical trial be an option for a baby with this condition?

Possibly. Because these disorders are rare, a specialist team may discuss research studies testing newer treatments that are not widely available; participation is voluntary and the team should explain the potential benefits, risks, and alternatives.

Get notified when new evidence is published on Neonatal erythroderma-autoinflammation-inflammatory bowel disease syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (20)

1
Proposal for a 6-step approach for differential diagnosis of neonatal erythroderma.
Cuperus E, Bygum A, Boeckmann L, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV 2022; (36(7)):973-986 doi:10.1111/jdv.18043.
PMID: 35238435
2
Inborn Errors of Immunity in Children with Autoimmune and Allergic Complaints: A Single Center Experience from Diagnosis to Treatment.
Boz V, Tesser A, Girardelli M, et al.
Biomedicines 2023; (11(5)) doi:10.3390/biomedicines11051299.
PMID: 37238969
3
Netherton Syndrome in a preterm newborn presenting with erythroderma and temperature instability: a case report.
Rossos AEM, Levy R, Ansari NS
BMC pediatrics 2026; (26(1)).
PMID: 41981412
4
Nutritional Management of the Critically Ill Neonate: A Position Paper of the ESPGHAN Committee on Nutrition.
Moltu SJ, Bronsky J, Embleton N, et al.
Journal of pediatric gastroenterology and nutrition 2021; (73(2)):274-289 doi:10.1097/MPG.0000000000003076.
PMID: 33605663
5
The clinical, molecular, and therapeutic features of patients with IL10/IL10R deficiency: a systematic review.
Sharifinejad N, Zaki-Dizaji M, Sepahvandi R, et al.
Clinical and experimental immunology 2022; (208(3)):281-291 doi:10.1093/cei/uxac040.
PMID: 35481870
6
Erythroderma (exfoliative dermatitis). Part 2: energy homeostasis and dietetic management strategies.
Tso S, Moiz H, Satchwell F, et al.
Clinical and experimental dermatology 2021; (46(6)):1011-1015 doi:10.1111/ced.14667.
PMID: 33817816
7
Turkish Neonatal Society guideline on neonatal infections-diagnosis and treatment.
Satar M, Arısoy AE, Çelik İH
Turk pediatri arsivi 2018; (53(Suppl 1)):S88-S100 doi:10.5152/TurkPediatriArs.2018.01809.
PMID: 31236022
8
Reducing postoperative hypothermia in infants: Quality improvement in China.
Qiu Q, Yang Z, Zhang Y, et al.
Paediatric anaesthesia 2024; (34(8)):773-782 doi:10.1111/pan.14910.
PMID: 38775778
9
Case Report: Novel IL10RB variant causing very early onset-inflammatory bowel disease.
Usman Y, Ptak CP, Cohran VC, et al.
Frontiers in immunology 2025; (16()):1655475 doi:10.3389/fimmu.2025.1655475.
PMID: 41122180
10
Successful Use of Anakinra in a Patient with IL-10R Beta Deficiency: A Case Report.
Dogan S, Selen R, Ozbay Hosnut F, et al.
Pediatric allergy, immunology, and pulmonology 2025; (38(1)):32-35 doi:10.1089/ped.2024.0116.
PMID: 39950990
11
An animal model of NLRC4-associated autoinflammation and infantile enterocolitis reveals novel therapeutic strategies.
Wang Y, Gao JZ, Gurung P, et al.
Cellular & molecular immunology 2025; (22(12)):1567-1580 doi:10.1038/s41423-025-01355-x.
PMID: 41116055
12
Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease.
Shaul E, Conrad MA, Dawany N, et al.
Frontiers in immunology 2022; (13()):972114 doi:10.3389/fimmu.2022.972114.
PMID: 36203564
13
Severe Combined Immunodeficiency Disorders.
Chinn IK, Shearer WT
Immunology and allergy clinics of North America 2015; (35(4)):671-94.
PMID: 26454313
14
Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study.
Heimall J, Logan BR, Cowan MJ, et al.
Blood 2017; (130(25)):2718-2727 doi:10.1182/blood-2017-05-781849.
PMID: 29021228
15
Anti-TNF-refractory inflammatory bowel disease associated with a novel XIAP frameshift variant successfully treated with ustekinumab.
Ito N, Kudo T, Eguchi H, et al.
Clinical journal of gastroenterology 2026; doi:10.1007/s12328-026-02394-1.
PMID: 42771130
16
Phenotype, genotype, treatment, and survival outcomes in patients with X-linked inhibitor of apoptosis deficiency.
Yang L, Booth C, Speckmann C, et al.
The Journal of allergy and clinical immunology 2022; (150(2)):456-466 doi:10.1016/j.jaci.2021.10.037.
PMID: 34920033
17
Cord Blood Transplantation for Very Early-Onset Inflammatory Bowel Disease Caused by Interleukin-10 Receptor Deficiency.
Wang P, Qian X, Jiang W, et al.
Journal of clinical immunology 2024; (44(3)):67 doi:10.1007/s10875-024-01669-x.
PMID: 38372823
18
Targeted therapies and their outcomes in monogenic very early onset inflammatory bowel disease: a systematic review.
Abhari AP, Rezvanian P, Sohrabi E, et al.
BMC gastroenterology 2026; (26(1)):113 doi:10.1186/s12876-025-04592-6.
PMID: 41540376
19
SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery.
Haddad E, Logan BR, Griffith LM, et al.
Blood 2018; (132(17)):1737-1749 doi:10.1182/blood-2018-03-840702.
PMID: 30154114
20
Precision medicine in monogenic inflammatory bowel disease: proposed mIBD REPORT standards.
Uhlig HH, Booth C, Cho J, et al.
Nature reviews. Gastroenterology & hepatology 2023; (20(12)):810-828 doi:10.1038/s41575-023-00838-4.
PMID: 37789059

This page is for informational purposes only and does not constitute medical advice. Treatment for a newborn with erythroderma, autoinflammation, and VEO-IBD must be directed by the baby’s specialist team.